文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

预防性泼尼松龙预防甲状腺癌放射性碘治疗早期和中期不良反应:单中心II/III期随机双盲安慰剂对照试验方案

Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2020-09-29

本研究为单中心II/III期随机双盲安慰剂对照平行臂试验,纳入接受放射性碘治疗的 differentiate 甲状腺癌患者,每组200例。实验组在RAI治疗前6小时单次口服泼尼松龙0.5 mg/kg和奥美拉唑20 mg,随后每日口服泼尼松龙0.5 mg/kg和奥美拉唑20 mg共3天;对照组使用安慰剂和奥美拉唑。主要比较两组与RAI及泼尼松龙治疗相关的临床显著不良反应和生活质量参数。

要点

  • 预防性泼尼松龙方案为RAI前6小时单次0.5 mg/kg,随后每日0.5 mg/kg共3天。
  • 试验为II/III期随机双盲安慰剂对照设计,每组200例。
  • 主要评估RAI相关临床显著不良反应及生活质量参数。

核心结论

  • 该试验将评估短期预防性糖皮质激素能否预防分化型甲状腺癌患者RAI治疗的早期和中期不良反应。

研究设计与样本

  • 单中心、II/III期、随机、双盲、安慰剂对照、平行臂临床试验,在斯里兰卡国家癌症研究所开展。
  • 计划纳入接受RAI治疗的分化型甲状腺癌患者,随机分为两组,每组200例。

关键数值与推荐

  • 实验组:RAI前6小时单次口服泼尼松龙0.5 mg/kg和奥美拉唑20 mg,随后每日口服泼尼松龙0.5 mg/kg和奥美拉唑20 mg共3天。
  • 对照组:RAI前6小时单次口服安慰剂和奥美拉唑20 mg,随后每日口服安慰剂和奥美拉唑20 mg共3天。
  • 比较两组与RAI及泼尼松龙治疗相关的临床显著不良反应和生活质量参数。

临床怎么用

  • 若证实有益,该预防性干预可纳入标准实践,以减少甲状腺癌RAI治疗的早期和中期不良反应并可能改善生活质量。

局限性

  • 单中心设计可能限制结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioactive iodine (RAI) therapy is the standard adjuvant treatment for differentiated thyroid cancer (i.e. papillary and follicular). RAI is associated with troublesome early, intermediate and late adverse effects. Although glucocorticoids are used for the management of these adverse effects, there is little evidence regarding the effectiveness of prophylactic glucocorticoids to prevent these complications. This trial will evaluate the efficacy of a short course of prophylactic glucocorticoids in the prevention of adverse effects of RAI treatment in patients with differentiated thyroid cancer. METHODS: A phase II/III, single-centre, randomized, double-blinded, placebo-controlled, parallel-arm clinical trial will be conducted. Patients with differentiated thyroid cancer who are referred to RAI therapy at the National Cancer Institute, Sri Lanka, will be randomized into two arms consisting of 200 patients each. The experimental group will receive prophylactic oral prednisolone 0.5 mg/kg and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral prednisolone 0.5 mg/kg and omeprazole 20 mg daily for 3 days. The control group will receive oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days. Clinically significant adverse effects assessed as related to RAI as well as prednisolone therapy and the quality of life parameters will be compared between the two groups. DISCUSSION: If proven beneficial, this intervention can be incorporated into the standard practice to reduce early and intermediate adverse effects of RAI for thyroid cancer with a potential improvement of quality of life. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry SLCTR/2020/009 . Registered prospectively on 23 February 2020. Items of the WHO Trial Registration Data Set are provided in the supplementary file.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jayarajah U, Wijekoon M, Seneviratne SA, et al. Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial. Trials. 2020. PMID: 32993815. doi:10.1186/s13063-020-04744-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。